This page shows what was measured, who it was measured in, and what that does not settle.
What Degarelix does in the body
Treatment of patients with advanced prostate cancer
From the FDA-approved label: Degarelix is a GnRH receptor antagonist. It binds reversibly to the pituitary GnRH receptors, thereby reducing the release of gonadotropins and consequently testosterone.
What happened in people
RNAWiki has not yet published a reviewed conclusion for this use.
§ A fixed RNAWiki sentence
Where this came from
Wording RNAWiki always uses, not a finding about this substance.
No reviewed claim names a result for any goal on this record.
No source is stored against this line.
The limit that matters most
Not recorded.
Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
What the registries record it as
Its recorded molecular formula is C82H103N18O16Cl, weighing 1632.3 Da.
US prescribing information · ab11dd8a-0fd9-4013-89ab-e114557c7e4b · read 2026-08-30
Where each sentence above came from
No recorded sentence describes the change this makes in a way that stands on its own. The page opens with what it is taken for instead, and the recorded explanation follows below.
Shown as the opening line on this page.
No statement of the main limit is recorded.
The four opening statements run to 47 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Stand-in result
A stand-in result is a number measured because the real result takes too long.
A picture of it, and where the picture fails
It is like judging a journey by the speedometer rather than by arriving.
Where that stops being true. Speed does predict arrival. Many stand-in results do not predict the real one.
What people get wrong. A stand-in result is often reported as the result itself.
A surrogate endpoint substituted for a clinical endpoint, valid only where the substitution has been shown to hold.
Enzyme
An enzyme is a protein that speeds up one chemical change.
A picture of it, and where the picture fails
An enzyme is like a machine on a production line doing one cut.
Where that stops being true. A machine is switched on and off by a person. Enzymes are controlled by the cell.
What people get wrong. Enzymes are thought to be used up. They are not; they work again and again.
A catalytic protein that lowers the activation energy of a specific reaction.
Receptor
A receptor is a part of a cell that a signal fits into.
A picture of it, and where the picture fails
A receptor is like a lock waiting for one key.
Where that stops being true. A lock either opens or does not. A receptor can be half-triggered, or worn out.
What people get wrong. Fitting a receptor is read as causing a benefit. It causes a step, and nothing more.
A protein that binds a specific ligand and converts that binding into a cellular response.
Pathway
A pathway is a chain of steps inside a cell, each one setting off the next.
A picture of it, and where the picture fails
A pathway is like a row of dominoes.
Where that stops being true. Dominoes fall one way. Pathways loop back and can switch themselves off.
What people get wrong. Changing one step is read as changing the outcome. Other steps often absorb it.
An ordered series of molecular interactions producing a defined cellular change.
What happened in people◇Read from sources, not yet reviewed
What was measured, goal by goal
One row for each goal a registered study measured something for. One column for each kind of thing that could be measured.
Registered studies list 40 outcome measures that RNAWiki could read. A registered study says what someone planned to measure. It does not say what they found. 0 of the matched studies tested this substance, and 0 posted a result.
There is no single score. A strong test result and a weak life result are different facts.
Goals down the side, kinds of measurement across the top. Each cell says what kind of thing was registered, not what was found.
Goal
Life outcome
What a body can do
How a person feels
A test result
A step in the body
Harms
How long
Who was studied
Fertility and sexual health
∅Nothing in the sources checkedNo registered study lists a life outcome for this goal.
∅Nothing in the sources checkedNo registered study lists a performance measure for this goal.
∅Nothing in the sources checkedNo registered study lists a symptom measure for this goal.
∅Nothing in the sources checkedNo registered study lists a test result for this goal.
∅Nothing in the sources checkedNo registered study lists a body-step measure for this goal.
—Not recordedHarms were not a registered measure for this goal.
—Not recordedNo finished study window is recorded.
…Waiting for a reviewerWho was studied is listed further down the page.
Body weight
∅Nothing in the sources checkedNo registered study lists a life outcome for this goal.
∅Nothing in the sources checkedNo registered study lists a performance measure for this goal.
∅Nothing in the sources checkedNo registered study lists a symptom measure for this goal.
△Only a number moved1 registered test measure.
∅Nothing in the sources checkedNo registered study lists a body-step measure for this goal.
—Not recordedHarms were not a registered measure for this goal.
—Not recordedNo finished study window is recorded.
…Waiting for a reviewerWho was studied is listed further down the page.
Which registered measures put each goal on this table
Fertility and sexual health
testosterone 0 5ng/ from day 28 through day 364; testosterone measurement; cumulative probability of testosterone at castrate level
Body weight
markedly abnormal values in vital signs and body weight
Sorted by fixed word lists, version v1. A name the rules do not recognise stays unsorted rather than moving to the nearest column.
What each mark on this table means
∅ Nothing in the sources checked
No registered study lists a life outcome for this goal.
— Not recorded
Harms were not a registered measure for this goal.
… Waiting for a reviewer
Who was studied is listed further down the page.
△ Only a number moved
1 registered test measure.
What happened in people◇Read from sources, not yet reviewed
What happened in people
Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.
Metastasis-free survival (MFS)
✗ The study did not show it
Who was studied
NCT04513717
How many people
2753
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Subcutaneous
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
FDA label (openFDA SPL) · a recorded source, not a stored snapshot
Progression-Free Survival
✗ The study did not show it
Who was studied
NCT00303784
How many people
2200
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Subcutaneous
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
FDA label (openFDA SPL) · a recorded source, not a stored snapshot
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Subcutaneous
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
FDA label (openFDA SPL) · a recorded source, not a stored snapshot
Percentage of Participants Alive (Overall Survival)
✗ The study did not show it
Who was studied
NCT00936390
How many people
1538
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Subcutaneous
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
FDA label (openFDA SPL) · a recorded source, not a stored snapshot
Overall survival (primary efficacy)
✗ The study did not show it
Who was studied
NCT07751133
How many people
1500
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Subcutaneous
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
FDA label (openFDA SPL) · a recorded source, not a stored snapshot
Overall survival (OS)
✗ The study did not show it
Who was studied
NCT03678025
How many people
1273
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Subcutaneous
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
FDA label (openFDA SPL) · a recorded source, not a stored snapshot
What we know
RNAWiki holds 6 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.
What happened in people◇Read from sources, not yet reviewed
How close this is to real life
The top step is something a person would feel or care about. The bottom is a guess from software. Filled steps are where evidence exists for this substance.
■Living longer, or avoiding a major eventEvidence recorded. Death, a heart attack, a stroke, a hospital stay.2 registered measures of this kind. 5 written-up studies measured this and did not show a benefit.
□What a body can do day to dayNo evidence recorded. Walking, dressing, breathing, recovering.No registered study measures this.
□Measured performanceNo evidence recorded. How much was lifted, how far was run, how fast.No registered study measures this.
■Symptoms and quality of lifeEvidence recorded. Pain, tiredness, mood, sleep, as the person rated it.2 registered measures of this kind.
■A number that stands in for healthEvidence recorded. Cholesterol, blood sugar, bone density. A stand-in, not the thing itself.5 registered measures of this kind.
■A step measured inside a personEvidence recorded. Something measured in human tissue or human cells.A human record sits on the stored organism ladder.
■AnimalsEvidence recorded. Mice, rats, dogs. Useful for ideas, not proof about people.Stored records in Mouse. A result in animals says what to test next. It does not say what happens in people.
■Cells in a dishEvidence recorded. Cells or chemistry on a bench, far from a whole body.Stored mechanism abstracts describe steps measured in cells or tissue.
□A guess from softwareNo evidence recorded. Nobody measured it. RNAWiki never publishes one as a finding.RNAWiki stores no prediction for this record. Software can suggest a link. RNAWiki does not publish one as a finding.
Higher on these steps means closer to something a person would feel. It does not mean better done.
What it would be like to take◇Read from sources, not yet reviewed
Felt, measured, or meaningful
Three different things that get called the same word. Registered studies measured all three, and mixing them is how a blood test becomes a health claim.
Felt
Things a person could notice without a test.
total international prostate symptom at week 12
international prostate symptom
Measured
Things only a test, a scale or a device shows.
liver function tests
markedly abnormal values in vital signs and body weight
serum psa levels 4 0
serum psa
maximum plasma concentration observed
Meaningful
Things that change how a life goes, not only a number.
progression free survival
prostate specific antigen free survival
A registered study says what someone planned to measure. It does not say what they found. A number moving is not the same as a life going better. The two are shown apart here.
Felt, but not shown to help. A person notices a change. No study showed it leads anywhere good.
Measured, but not felt. A number moves. The person notices nothing. Both can be true.
Measured, but not shown to matter. A number moves in the good direction. Nobody showed that lives went better.
Matters, but takes years. The result that counts may take longer than anyone would keep watching.
Names that fit none of the three (31)
testosterone 0 5ng/ from day 28 through day 364
markedly abnormal values in safety laboratory variables
prostate volume
prostate size based on trans rectal ultra sound at week 12
alive
testosterone measurement
who progressed after 7 months of being on treatment
psa progression
intratumoral androgen levels
pregnancy rate
ovarian hyperstimulation syndrome rate
cumulative probability of testosterone at castrate level
cd4+ t cell count of greater than 200
soft tissue complete response
biostatistical analysis
n cadherin and vimentin expression
time to optimal ovarian function suppression
number and percentage of adverse events
ecg parameters
clinically significant changes in laboratory values
These are harms, study-process measures, or names the rules did not recognise. They are shown rather than dropped.
What is missing or unclear◇Read from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
People similar to this profile were included.
FIRMAGON ® is indicated for treatment of patients with advanced prostate cancer. FIRMAGON is a GnRH receptor antagonist indicated for treatment of patients with advanced prostate cancer. ( 1 )
Who is missing from the studies
Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What the label states about particular groups
On pediatric, the label states: “Safety and effectiveness in pediatric patients have not been established.”
US prescribing information · ab11dd8a-0fd9-4013-89ab-e114557c7e4b · read 2026-08-30
On older people, the label states: “Of the total number of subjects in clinical studies of FIRMAGON, 82% were age 65 and over, while 42% were age 75 and over.”
US prescribing information · ab11dd8a-0fd9-4013-89ab-e114557c7e4b · read 2026-08-30
On people who are pregnant, the label states: “Risk Summary The safety and efficacy of FIRMAGON have not been established in women.”
US prescribing information · ab11dd8a-0fd9-4013-89ab-e114557c7e4b · read 2026-08-30
On people who are breastfeeding, the label states: “The safety and efficacy of FIRMAGON have not been established in females.”
US prescribing information · ab11dd8a-0fd9-4013-89ab-e114557c7e4b · read 2026-08-30
On people with reduced liver function, the label states: “A single dose of 1 mg degarelix administered as an intravenous infusion over 1 hour was studied in 16 non-prostate cancer patients with either mild (Child Pugh A) or moderate (Child Pugh B) hepatic impairment.”
US prescribing information · ab11dd8a-0fd9-4013-89ab-e114557c7e4b · read 2026-08-30
On people with reduced kidney function, the label states: “No pharmacokinetic studies in renally impaired patients have been conducted.”
US prescribing information · ab11dd8a-0fd9-4013-89ab-e114557c7e4b · read 2026-08-30
Where the result stopped carrying
This is a scope explorer, not a diagnosis engine.
It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to take◇Read from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
It was studied for a different goal
The studies measured something else entirely.
On this record: Some registered studies measured things that match no goal on this page.
It was studied in different people
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
The evidence may simply be wrong
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (10)
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to take◇Read from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Given by a clinician
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Subcutaneous
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form and route recorded on this substance.
No source is stored against this line.
Who oversees it
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Suppression classes recorded: S3.
No source is stored against this line.
What is in the pack
Sold as njection, powder, lyophilized, for solution, powder, given by the subcutaneous route.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on how this is sold and what that means for what is in the pack.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
# Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to take∅Nothing found in the sources checked
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
∅Nothing found in the sources checked
No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.
The sources listed were searched and held nothing. That is not the same as nothing existing.
Reports sent to a regulator
These are reports people sent to a regulator. They do not show the medicine caused the reaction.
Nobody counted how many people took the medicine and reported nothing.
The same event can be reported more than once, and many reports are incomplete.
News coverage, lawsuits and new warnings change how often people report.
A count is not a rate and not a risk.
Degarelix appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 626 reaction mentions were counted. One report can name several reactions.
The recorded terms (10)
injection site pain — 125 reaction mentions
injection site erythema — 118 reaction mentions
injection site swelling — 80 reaction mentions
pyrexia — 59 reaction mentions
hot flush — 46 reaction mentions
injection site reaction — 45 reaction mentions
prostatic specific antigen increased — 43 reaction mentions
injection site induration — 42 reaction mentions
chills — 36 reaction mentions
injection site mass — 32 reaction mentions
open-targets-adr · recorded 2026-06-24 · a recorded source, not a stored snapshot
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclear◇Read from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Subcutaneous
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form used in the studies cited on this page.
No source is stored against this line.
What is sold
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
Nothing further is recorded about which forms are sold.
No source is stored against this line.
What is recorded as being sold
17 products list this as an active ingredient in the United States drug directory. 17 of them contain it and nothing else.
FDA National Drug Code directory · 14799-4001 · read 2026-08-29
They are sold as powder.
FDA National Drug Code directory · 14799-4001 · read 2026-08-29
1 published label names it as an active ingredient. 1 of them describe this substance alone, which is where its own label text on this page comes from.
US prescribing information · ab11dd8a-0fd9-4013-89ab-e114557c7e4b · read 2026-08-29
Those labels are classed as human prescription drug.
US prescribing information · ab11dd8a-0fd9-4013-89ab-e114557c7e4b · read 2026-08-29
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
What it would be like to take◇Read from sources, not yet reviewed
What you could measure
This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.
Self-experiment planning is not offered for a prescription or clinician-supervised medicine. The questions below are for a clinician or pharmacist.
Questions worth asking
Which of the trials of Degarelix studied people like me?
What was measured, and for how long?
Was the result a laboratory value or a health outcome?
What would we watch for, and when would we stop?
Tracking can show whether something changed for you. It cannot show what caused it.
RNAWiki records evidence. It does not say whether this substance is right for you.
What is missing or unclear◇Read from sources, not yet reviewed
What nobody knows yet
Open questions, each with why it is open and what would close it.
Missing populations
Which groups were under-represented in the studies has not been recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing long-term data
No completed tested study window is recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
No reviewed conclusion
RNAWiki has not yet published a reviewed conclusion for this use.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing interaction studies
No interaction was found in the registers checked. Not finding one is not the same as showing there is none.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Formulation uncertainty
Several salts, forms or products of Degarelix are recorded. Results from one form may not transfer to another.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Mechanism not reviewed
No reviewed mechanism story exists for this substance.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
What happened in people∅Nothing found in the sources checked
Check any of this yourself
Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.
∅Nothing found in the sources checked
No traced study record is stored for this substance.
The sources listed were searched and held nothing. That is not the same as nothing existing.
Checks this page had to pass
✓ Passed
Identity resolved
no open identity hold
✓ Passed
No unresolved merge across substance families
no quarantine open
✓ Passed
Every public sentence names a source
The opening statement carries the origin: Written into the record, not signed off.
✗ Not passed
Trial roles classified for highlighted evidence
No registered study is classified as testing this substance.
✓ Passed
No internal keys in reader text
enforced by the copy-contract test over the rendered page
✓ Passed
Safety mode resolved
Suppression classes recorded: S3.
✓ Passed
Canonical metadata present
slug and display name present
What is missing or unclear◇Read from sources, not yet reviewed
How this medicine reached us
Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.
What the approval register records
2 approved applications cover products containing this substance. The earliest was NDA022201, approved 20081224 to FERRING.
This order is fixed in code and does not count clicks or time on the page.
What is not here
6 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
The path through the body — found nothing in the sources checked.
How long anything takes — found nothing in the sources checked.
What it may clash with — found nothing in the sources checked.
Other ways to the same goal — found nothing in the sources checked.
Claims that go past the evidence — found nothing in the sources checked.
What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
Recorded evidence blocks (11)
Q2
What did Degarelix's largest trial (14417 people) and its longest (18 years) measure?
14417 people in Degarelix's largest registered study, 18 years in its longest registered window, measuring Composite of Mortality, Ongoing Need for Hospitalization, or Mechanical Ventilation at Day 15. ClinicalTrials.gov · 2026-09-01
68 phase2, 36 phase3, 11 na or unstated, 10 phase1, 9 phase4, 8 na, 2 early phase1; NCT04513717; 2038-12-31. Last human test completed 2026, NCT02020070.
Interpretation These counts include studies where Degarelix was a comparison treatment, a background treatment or an exposure in an observational study, and the longest window may be a planned end date. Trial roles have not yet been classified for this record.
Show the evidence
phase2
68
phase3
36
na or unstated
11
phase1
10
phase4
9
na
8
2 more recorded rows
early phase1
2
Last recorded human testNCT02020070
2026-06-30
recorded 2026-09-01 · last checked 2026-09-04
Q3
From mouse to human: where has Degarelix shown lifespan?
terminated; "Recruitment rate; a lower than anticipated observed cardiovascular event rate. The Sponsor decision to stop the trial was not based on any safety concerns or any knowledge of the results, or influenced by issues imposed by the COVID-19…"
NCT03056638
terminated; "Due to low accrual"
NCT04585932
withdrawn; "At the request of the ad interim Department Chairman due to PI is no longer at institution."
NCT05839119
terminated; "Principal Investigator left institution"
NCT06218667
withdrawn; "Study drug not available per sponsor"
NCT06528210
withdrawn; "Loss of funding"
recorded 2026-09-01 · last checked 2026-09-04
Q5
Human studies of Degarelix used Degarelix 80 mg / Degarelix 80 mg — over how long?
Which of alive, biostatistical analysis and cd4+ t cell count of greater than 200 did Degarelix's trials measure?
alive, biostatistical analysis and cd4+ t cell count of greater than 200 lead 40 outcome terms across Degarelix's trials. ClinicalTrials.gov · 2026-09-01
markedly abnormal values in safety laboratory variables, prostate volume, total international prostate symptom at week 12, prostate size based on trans rectal ultra sound at week 12, serum psa levels 4 0 and alive follow.
Show the evidence
liver function tests
1
markedly abnormal values in vital signs and body weight
1
testosterone 0 5ng/ from day 28 through day 364
1
markedly abnormal values in safety laboratory variables
1
prostate volume
1
total international prostate symptom at week 12
1
14 more recorded rows
prostate size based on trans rectal ultra sound at week 12
1
serum psa levels 4 0
1
alive
1
international prostate symptom
1
testosterone measurement
1
who progressed after 7 months of being on treatment
1
serum psa
1
psa progression
1
intratumoral androgen levels
1
pregnancy rate
1
ovarian hyperstimulation syndrome rate
1
cumulative probability of testosterone at castrate level
1
cd4+ t cell count of greater than 200
1
progression free survival
1
recorded 2026-09-01 · last checked 2026-09-04
Q7
Which of Degarelix's 34 ongoing trials reports first?
a CD4+ T cell count of greater than 200; Prostate-specific antigen (PSA) free survival (PSA < 0.1 ng/ml); latest 2038-12-31
Show the evidence
Trial
NCT01746849
"Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation"; n 82; "a CD4+ T cell count of greater than 200"; 2026-12
NCT01786265
"Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer"; n 310; "Prostate-specific antigen (PSA) free survival (PSA < 0.1 ng/ml)"; 2027-02-01
NCT01990196
"Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer"; n 45; "N-cadherin and vimentin expression"; 2026-09-30
NCT01994239
"Comparison of HT Concomitant With RT vs RT Alone in Patients With a Detectable PSA After Prostatectomy"; n 120; "The efficacy of the combination of hormonal therapy by degarelix and radiotherapy on event-free survival"; 2025-03
NCT02799706
"Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer"; n 885; "Progression free survival"; 2026-06-30
NCT03361735
"Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer"; n 25; "Time to Treatment Failure"; 2027-01-06
14 further recorded trials
NCT03678025
"Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer"; n 1273; "Overall survival (OS)"; 2031-10-01
NCT03689699
"Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)"; n 59; "Number of Participants With Prostate-specific Antigen (PSA) Recurrence"; 2026-01
NCT03703778
"Real-life Evaluation of the Effect of ADT in Prostate Cancer Patients in Asia (READT Asia Study)"; n 300; "The proportion of patients using surgical castration and medical castration in prostate cancer patients in Asia"; 2026-03-31
NCT03951831
"REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer"; n 26; "Percentage of Subjects Achieving Undetectable PSA at 6 months after Combination Treatment"; 2028-04
NCT04043520
"Bioenergetic Effects of Aging and Menopause (BEAM)"; n 57; "Change in the Microdialysis Cortisone Challenge (MCC) Index"; 2024-08-31
NCT04126070
"Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors"; n 47; "Percentage of Subjects With Prostate Specific Antigen (PSA) Less Than or Equal to 0.2 ng/mL at 7 Months From Start of Chemoimmunotherapy"; 2026-10-30
NCT04176081
"Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate Cancer"; n 208; "Recurrence Free Survival"; 2028-12
NCT04423211
"Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging"; n 804; "Progression-free survival (PFS)"; 2032-12-31
NCT04455750
"A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy"; n 61; "Radiographic progression-free survival (rPFS)"; 2027-09
NCT04513717
"Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial"; n 2753; "Metastasis-free survival (MFS)"; 2038-12-31
NCT04734730
"Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer"; n 70; "Prostate specific antigen (PSA) nadir < 0.2"; 2027-08-23
NCT04989946
"Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer"; n 57; "Pathological Complete Response Rate (pCR)"; 2028-12
NCT05050084
"Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial"; n 2050; "Distant metastasis (DM) (De-intensification study)"; 2031-11-11
NCT05057546
"Ovarian Hormone Regulation of Central and Cerebrovascular Hemodynamics (NoMEN Study)"; n 55; "Aortic stiffness and pulsatile hemodynamics"; 2025-07-28
recorded 2026-09-01 · last checked 2026-09-04
Q8
Which running trial of Degarelix could settle lifespan?
NCT01994239 measures The efficacy of the combination of hormonal therapy by degarelix and radiotherapy on event-free survival, reading out 2025-03.
12 open trials; n 120; "Comparison of HT Concomitant With RT vs RT Alone in Patients With a Detectable PSA After Prostatectomy"
Show the evidence
Trial
NCT01994239
"Comparison of HT Concomitant With RT vs RT Alone in Patients With a Detectable PSA After Prostatectomy"; n 120; "The efficacy of the combination of hormonal therapy by degarelix and radiotherapy on event-free survival"; 2025-03
NCT02799706
"Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer"; n 885; "Progression free survival"; 2026-06-30
NCT01786265
"Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer"; n 310; "Prostate-specific antigen (PSA) free survival (PSA < 0.1 ng/ml)"; 2027-02-01
NCT04455750
"A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy"; n 61; "Radiographic progression-free survival (rPFS)"; 2027-09
NCT05189457
"First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer"; n 32; "Overall Survival"; 2028-07
NCT04176081
"Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate Cancer"; n 208; "Recurrence Free Survival"; 2028-12
6 further recorded trials
NCT06282588
"Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers"; n 493; "Phase 3: PSMA PET metastasis free survival (ppMFS)"; 2030-12-31
NCT06378866
"Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial"; n 532; "Modified radiographic progression-free survival (mrPFS) (Groups A & B)"; 2031-02-28
NCT06922318
"The COSMYC Trial (COmbined Suppression of MYC)"; n 50; "Clinical/radiographic progression free survival (PFS) with BATZEN"; 2031-08-30
NCT03678025
"Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer"; n 1273; "Overall survival (OS)"; 2031-10-01
NCT04423211
"Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging"; n 804; "Progression-free survival (PFS)"; 2032-12-31
NCT04513717
"Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial"; n 2753; "Metastasis-free survival (MFS)"; 2038-12-31
Q9
Which 28 trials of Degarelix posted no result?
Posted no result
28 of 28 completed trials
Registrations
NCT00568516, NCT01261572, NCT01344564, NCT01491971, NCT01744366 and NCT01710098, and 22 more
Completion dates
oldest 2009-10; newest 2024-04-03
Show the evidence
Trial
NCT00568516
2009-10
NCT01261572
2012-04-24
NCT01344564
2012-08
NCT01491971
2012-11
NCT01744366
2015-05
NCT01710098
2015-09-24
14 further recorded trials
NCT01674270
2015-11
NCT01709942
2015-12
NCT01712763
2016-03
NCT01964170
2016-08-08
NCT02526784
2017-06
NCT02015871
2017-08-01
NCT02229253
2017-10-04
NCT02468284
2017-10-10
NCT01446991
2017-12
NCT01861236
2018-09-03
NCT01862835
2018-12-30
NCT03193645
2019-01-31
NCT02886598
2019-03-26
NCT02324998
2019-05
Q10
At the median, Degarelix's trials enrolled 82 people — anything larger?
Median enrolment
82
Largest enrolment
14417
Registered trials counted
135
Q11
What do 626 spontaneous reports say about Degarelix — and not say?
These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.
Degarelix appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 626 reaction mentions were counted: injection site pain 125; injection site erythema 118; injection site swelling 80; pyrexia 59. open-targets-adr · CHEMBL2028987 · 2026-06-24
Show the evidence
injection site pain
125
injection site erythema
118
injection site swelling
80
pyrexia
59
hot flush
46
injection site reaction
45
4 more recorded rows
prostatic specific antigen increased
43
injection site induration
42
chills
36
injection site mass
32
recorded 2026-06-24 · last checked 2026-09-04
Q12
What is recorded about Degarelix and autophagy?
"The effect of degarelix could be reversed by 3-methyladenine (3-MA), which inhibits the class III phosphatidylinositol (PI) 3 kinase required for autophagy initiation." — where Degarelix and autophagy appear together. Europe PMC · pathway abstract search · 2024-10-20
autophagy; PMID 39433139
Show the evidence
autophagyPMID 39433139
"The effect of degarelix could be reversed by 3-methyladenine (3-MA), which inhibits the class III phosphatidylinositol (PI) 3 kinase required for autophagy initiation."
recorded 2024-10-20 · last checked 2026-09-04
Where it is registeredIdentifiers, relations and other names
ClinicalTrials.gov — US Government work · Europe PMC — metadata only, under the recorded legal gate · Open Targets 26.06 — CC0 · derived from this page's own recorded fields; no external licence · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work
✗ required summary fields resolved: 5 required field(s) not terminal: Why people use it, Best-supported result, Most important common problem, Biggest unanswered question, Human evidence
✓ public claims reviewed: 0 reviewed claim(s); drafts are never rendered
✓ source coverage passed: 10 source rows
✓ no critical contamination: no quarantine open
✓ canonical metadata passed: slug and display name present
✓ no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.